Abstract
Introduction
Neuroblastoma is a childhood cancer of neural crest cells occasionally associated with opsoclonus–myoclonus–ataxia syndrome (OMAS), a paraneoplastic process characterized by ataxia, rapid eye movements, and muscle twitching. OMAS treatment and outcomes are well studied, but prior reports do not detail how the presence of OMAS should impact surgical approach, particularly for tumors with image defined risk factors (IDRF).
Methods
We reviewed patients with neuroblastoma and OMAS at our institution from January 2009 to December 2020 and recorded tumor characteristics, operative details, OMAS therapies, and outcomes.
Results
We identified 14 patients with neuroblastoma and OMAS out of 212 patients referred for surgery. There were 11 gross total resections and three partial resections. Two patients with partial resections developed OMAS after initial resection. One patient with gross total resection developed tumor recurrence 10 years later with OMAS redevelopment signaling recurrence. Three patients were positive for IDRFs and the one receiving neoadjuvant therapy achieved a gross total resection.
Conclusions
OMAS development after partial resection and OMAS recurrence following tumor recurrence indicates a correlation between tumor bulk and the paraneoplastic process. This justifies an aggressive resection even for low-risk tumors. Neoadjuvant therapy should be considered for potentially unresectable tumors with image defined risk factors.
Level of evidence
IV.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- OMAS:
-
Opsoclonus–myoclonus–ataxia syndrome
- DI:
-
DNA index
- F/UF:
-
Favorable/unfavorable histology
- POD:
-
Post-operative day
References
Jackson JR, Kim ES (2017) Neuroblastoma. In: Mattei P et al (eds) Fundamentals of pediatric surgery. Springer International Publishing, New York, pp 767–775
Cooper R et al (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children’s Cancer Group. Med Pediatr Oncol 36(6):623–629
Mitchell WG et al (2002) Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequalae. Pediatrics 109(1):86–98
Oh SY, Kim JS, Dieterich M (2019) Update on opsoclonus-myoclonus syndrome in adults. J Neurol 266:1541–1548
Raffaghello L, Conte M, Grandis ED, Pistoia V (2009) Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma. Eur J Pediatr Neurol 13:219–223
Blaes F, Preissner KT et al (2005) Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 58(2):313–317
Pranzatelli MR, Verhulst SJ et al (2004) B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 62(9):1526–1532
Strother DR et al (2012) Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of children’s oncology group study P9641. J Clin Oncol 30(15):1842–1848
Gambini C et al (2003) Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistological and molecular features of 15 Italian cases. Virchows Arch 442:555–562
Pranzatelli MR, Tate ED (2017) Dexamethasone, intravenous immunoglobulin, and rituximab combination immunotherapy for pediatric opsoclonus-myoclonus syndrome. Pediatr Neurol 73:48–56
de Alarcon PA et al (2018) Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health 2(1):25–34
Tate ED, Pranzatelli MR, Verhulst SJ et al (2012) Active comparator controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome. J Child Neurol 27(7):875–884
Pranzatelli M, Tate E, Alber M et al (2018) Rituximab, IVIg, and tetracosactide (ACTH1-24) combination immunotherapy (“RITE-CI”) for pediatric opsoclonus-myoclonus syndrome: immunomarkers and clinical observations. Neuropediatrics 49(02):123–134
Pranzatelli MR, Tate ED, Travelstead AL et al (2006) Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 28:585–593
Russo C et al (1997) Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the pediatric oncology group. Med Pediatr Oncol 29:284–288
Tate ED et al (2005) Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 22(1):18–19
Patel A et al (2020) Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: the memorial sloan kettering experience. Pediatr Blood Cancer 67(8):e28319
Wilbur C, Yea C, Licht C, Irwin MS, Yeh EA (2019) An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome. Pediatr Blood Cancer 66(8):e27776
Acknowledgements
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Johnston, W.R., Hwang, R. & Mattei, P. Surgical considerations for neuroblastoma-associated opsoclonus–myoclonus–ataxia syndrome: a series of 14 patients from a single institution. Pediatr Surg Int 38, 249–255 (2022). https://doi.org/10.1007/s00383-021-05014-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00383-021-05014-w